Logo image of RNAC

CARTESIAN THERAPEUTICS INC (RNAC) Stock Price, Quote, News and Overview

NASDAQ:RNAC - Nasdaq - US8162123025 - Common Stock - Currency: USD

9.34  -0.2 (-2.1%)

After market: 9.34 0 (0%)

RNAC Quote, Performance and Key Statistics

CARTESIAN THERAPEUTICS INC

NASDAQ:RNAC (6/5/2025, 8:07:08 PM)

After market: 9.34 0 (0%)

9.34

-0.2 (-2.1%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High36.8
52 Week Low8.46
Market Cap242.37M
Shares25.95M
Float5.80M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06
IPO06-22 2016-06-22


RNAC short term performance overview.The bars show the price performance of RNAC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

RNAC long term performance overview.The bars show the price performance of RNAC in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of RNAC is 9.34 USD. In the past month the price decreased by -7.98%. In the past year, price decreased by -74.47%.

CARTESIAN THERAPEUTICS INC / RNAC Daily stock chart

RNAC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.25 331.15B
AMGN AMGEN INC 13.83 154.38B
GILD GILEAD SCIENCES INC 14.27 137.40B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.97B
REGN REGENERON PHARMACEUTICALS 10.9 52.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 40.16B
ARGX ARGENX SE - ADR 100.97 35.45B
ONC BEONE MEDICINES LTD-ADR 6.57 27.78B
BNTX BIONTECH SE-ADR N/A 26.48B
NTRA NATERA INC N/A 22.60B
BIIB BIOGEN INC 8.24 19.10B
SMMT SUMMIT THERAPEUTICS INC N/A 14.65B

About RNAC

Company Profile

RNAC logo image Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Frederick, Maryland and currently employs 66 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Company Info

CARTESIAN THERAPEUTICS INC

7495 New Horizon Way

Frederick MARYLAND US

Employees: 66

RNAC Company Website

RNAC Investor Relations

Phone: 13013488698

CARTESIAN THERAPEUTICS INC / RNAC FAQ

What is the stock price of CARTESIAN THERAPEUTICS INC today?

The current stock price of RNAC is 9.34 USD. The price decreased by -2.1% in the last trading session.


What is the ticker symbol for CARTESIAN THERAPEUTICS INC stock?

The exchange symbol of CARTESIAN THERAPEUTICS INC is RNAC and it is listed on the Nasdaq exchange.


On which exchange is RNAC stock listed?

RNAC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CARTESIAN THERAPEUTICS INC stock?

14 analysts have analysed RNAC and the average price target is 39.95 USD. This implies a price increase of 327.73% is expected in the next year compared to the current price of 9.34. Check the CARTESIAN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CARTESIAN THERAPEUTICS INC worth?

CARTESIAN THERAPEUTICS INC (RNAC) has a market capitalization of 242.37M USD. This makes RNAC a Micro Cap stock.


How many employees does CARTESIAN THERAPEUTICS INC have?

CARTESIAN THERAPEUTICS INC (RNAC) currently has 66 employees.


What are the support and resistance levels for CARTESIAN THERAPEUTICS INC (RNAC) stock?

CARTESIAN THERAPEUTICS INC (RNAC) has a resistance level at 9.45. Check the full technical report for a detailed analysis of RNAC support and resistance levels.


Is CARTESIAN THERAPEUTICS INC (RNAC) expected to grow?

The Revenue of CARTESIAN THERAPEUTICS INC (RNAC) is expected to decline by -91.16% in the next year. Check the estimates tab for more information on the RNAC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CARTESIAN THERAPEUTICS INC (RNAC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CARTESIAN THERAPEUTICS INC (RNAC) stock pay dividends?

RNAC does not pay a dividend.


When does CARTESIAN THERAPEUTICS INC (RNAC) report earnings?

CARTESIAN THERAPEUTICS INC (RNAC) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of CARTESIAN THERAPEUTICS INC (RNAC)?

CARTESIAN THERAPEUTICS INC (RNAC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.86).


What is the Short Interest ratio of CARTESIAN THERAPEUTICS INC (RNAC) stock?

The outstanding short interest for CARTESIAN THERAPEUTICS INC (RNAC) is 43.21% of its float. Check the ownership tab for more information on the RNAC short interest.


RNAC Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

RNAC Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RNAC. RNAC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RNAC Financial Highlights

Over the last trailing twelve months RNAC reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS increased by 88.73% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -10.39%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%93.52%
Sales Q2Q%-81.16%
EPS 1Y (TTM)88.73%
Revenue 1Y (TTM)35.14%

RNAC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 81% to RNAC. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 71.92% and a revenue growth -91.16% for RNAC


Ownership
Inst Owners27.24%
Ins Owners40.81%
Short Float %43.21%
Short Ratio26.31
Analysts
Analysts81.43
Price Target39.95 (327.73%)
EPS Next Y71.92%
Revenue Next Year-91.16%